Neisseria meningitidisfactor H-binding protein fHbp: a key virulence factor and vaccine antigen

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

(2014) Robert C Read et al.   LANCET

Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age

(2014) Fiona McQuaid et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain

(2014) Emilio Pérez-Trallero et al.   PLoS One

A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants

(2014) Federico Martinon-Torres et al.   VACCINE

Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway

(2014) Johan Holst et al.   VACCINE

Human Factor H (FH) Impairs Protective Meningococcal Anti-FHbp Antibody Responses and the Antibodies Enhance FH Binding

(2014) I. Costa et al.   mBio

A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)

(2014) Susanna Esposito et al.   Human Vaccines & Immunotherapeutics

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)

(2014) Roman Prymula et al.   Human Vaccines & Immunotherapeutics

The Discovery and Development of a Novel Vaccine to Protect againstNeisseria meningitidisSerogroup B Disease

(2014) Gary W Zlotnick et al.   Human Vaccines & Immunotherapeutics

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose

(2013) M. D. Snape et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Genetic Distribution of Noncapsular Meningococcal Group B Vaccine Antigens in Neisseria lactamica

(2013) Jay Lucidarme et al.   Clinical and Vaccine Immunology

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program

(2013) Miguel O’Ryan et al.   DRUGS

Two cross-reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties

(2013) Agnese Faleri et al.   FASEB JOURNAL

Nonfunctional Variant 3 Factor H Binding Proteins as Meningococcal Vaccine Candidates

(2013) Stijn van der Veen et al.   INFECTION AND IMMUNITY

Importance of Inhibition of Binding of Complement Factor H for Serum Bactericidal Antibody Responses to Meningococcal Factor H-binding Protein Vaccines

(2013) Monica Konar et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

(2013) Timo Vesikari et al.   LANCET

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

(2013) Ulrich Vogel et al.   LANCET INFECTIOUS DISEASES

Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease

(2013) L. K. McNeil et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

A Multi-country Evaluation of Neisseria meningitidis Serogroup B Factor H–Binding Proteins and Implications for Vaccine Coverage in Different Age Groups

(2013) Susan K. Hoiseth et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa

(2013) Rolando Pajon et al.   PLoS One

An Analysis of the Sequence Variability of Meningococcal fHbp, NadA and NHBA over a 50-Year Period in the Netherlands

(2013) Stefania Bambini et al.   PLoS One

Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen

(2013) Enrico Malito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations

(2013) Serena Giuntini et al.   VACCINE

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

(2013) Giacomo Frosi et al.   VACCINE

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

(2013) Helen S. Marshall et al.   VACCINE

Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice

(2013) Raffaella Rossi et al.   VACCINE

Conservation of Meningococcal Antigens in the Genus Neisseria

(2013) A. Muzzi et al.   mBio

Factor H-Dependent Alternative Pathway Inhibition Mediated by Porin B Contributes to Virulence of Neisseria meningitidis

(2013) L. A. Lewis et al.   mBio

Meningococcal disease and the complement system

(2013) Lisa A Lewis et al.   Virulence

Vaccines, Reverse Vaccinology, and Bacterial Pathogenesis

(2013) I. Delany et al.   Cold Spring Harbor Perspectives in Medicine

Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine

(2013) Maria Elena Santolaya et al.   Human Vaccines & Immunotherapeutics

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future

(2013) Johan Holst et al.   Human Vaccines & Immunotherapeutics

Potential impact of the bivalent rLP2086 vaccine onNeisseria meningitidiscarriage and invasive serogroup B disease

(2013) Annaliesa S. Anderson et al.   Human Vaccines & Immunotherapeutics

Distinct Binding and Immunogenic Properties of the Gonococcal Homologue of Meningococcal Factor H Binding Protein

(2013) Ilse Jongerius et al.   PLoS Pathogens

The Factor H Binding Protein of Neisseria meningitidis Interacts with Xenosiderophores in Vitro

(2012) Daniele Veggi et al.   BIOCHEMISTRY

Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines

(2012) Brian D. Plikaytis et al.   Clinical and Vaccine Immunology

Design of Meningococcal Factor H Binding Protein Mutant Vaccines That Do Not Bind Human Complement Factor H

(2012) Rolando Pajon et al.   INFECTION AND IMMUNITY

Transcriptional Regulation of thenadAGene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine

(2012) Luca Fagnocchi et al.   INFECTION AND IMMUNITY

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

(2012) Nicoletta Gossger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Relative Roles of Factor H Binding Protein, Neisserial Surface Protein A, and Lipooligosaccharide Sialylation in Regulation of the Alternative Pathway of Complement on Meningococci

(2012) L. A. Lewis et al.   JOURNAL OF IMMUNOLOGY

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

(2012) María Elena Santolaya et al.   LANCET

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

(2012) Peter C Richmond et al.   LANCET INFECTIOUS DISEASES

The effect of iron availability on transcription of the Neisseria meningitidis fHbp gene varies among clonal complexes

(2012) H. Sanders et al.   MICROBIOLOGY-SGM

A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents

(2012) Michael D. Nissen et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Monoclonal Antibodies to Meningococcal Factor H Binding Protein with Overlapping Epitopes and Discordant Functional Activity

(2012) Serena Giuntini et al.   PLoS One

Transcriptional Profiling of Serogroup B Neisseria meningitidis Growing in Human Blood: An Approach to Vaccine Antigen Discovery

(2012) Asa K. Hedman et al.   PLoS One

Functional impacts of the diversity of the meningococcal factor H binding protein

(2012) Eva Hong et al.   VACCINE

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial

(2012) P.C. Richmond et al.   VACCINE

A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults

(2012) Eric Sheldon et al.   Human Vaccines & Immunotherapeutics

The Effect of Human Factor H on Immunogenicity of Meningococcal Native Outer Membrane Vesicle Vaccines with Over-Expressed Factor H Binding Protein

(2012) Peter T. Beernink et al.   PLoS Pathogens

Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen Molecules

(2012) Steven Johnson et al.   PLoS Pathogens

Structure of the uncomplexedNeisseria meningitidisfactor H-binding protein fHbp (rLP2086)

(2011) Laura Cendron et al.   Acta Crystallographica Section F-Structural Biology and Crystallization Communications

A Critical Threshold of Meningococcal Factor H Binding Protein Expression Is Required for Increased Breadth of Protective Antibodies Elicited by Native Outer Membrane Vesicle Vaccines

(2011) Oliver Koeberling et al.   Clinical and Vaccine Immunology

Characterization of Neisseria meningitidis Isolates That Do Not Express the Virulence Factor and Vaccine Antigen Factor H Binding Protein

(2011) Jay Lucidarme et al.   Clinical and Vaccine Immunology

The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans

(2011) Daniela Toneatto et al.   Human vaccines & immunotherapeutics

Enhanced Bacteremia in Human Factor H Transgenic Rats Infected by Neisseria meningitidis

(2011) David M. Vu et al.   INFECTION AND IMMUNITY

Combined Roles of Human IgG Subclass, Alternative Complement Pathway Activation, and Epitope Density in the Bactericidal Activity of Antibodies to Meningococcal Factor H Binding Protein

(2011) Serena Giuntini et al.   INFECTION AND IMMUNITY

Complement-Mediated Bactericidal Activity of Anti-Factor H Binding Protein Monoclonal Antibodies against the Meningococcus Relies upon Blocking Factor H Binding

(2011) Serena Giuntini et al.   INFECTION AND IMMUNITY

In the NadR Regulon, Adhesins and Diverse Meningococcal Functions Are Regulated in Response to Signals in Human Saliva

(2011) L. Fagnocchi et al.   JOURNAL OF BACTERIOLOGY

A Meningococcal Factor H Binding Protein Mutant That Eliminates Factor H Binding Enhances Protective Antibody Responses to Vaccination

(2011) P. T. Beernink et al.   JOURNAL OF IMMUNOLOGY

Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity

(2011) M. Scarselli et al.   Science Translational Medicine

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys

(2011) Oliver Koeberling et al.   VACCINE

Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates

(2011) Jane W. Marsh et al.   VACCINE

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States

(2011) Xin Wang et al.   VACCINE

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression

(2011) P.B. Keiser et al.   VACCINE

Transcriptome Analysis of Neisseria meningitidis in Human Whole Blood and Mutagenesis Studies Identify Virulence Factors Involved in Blood Survival

(2011) Hebert Echenique-Rivera et al.   PLoS Pathogens

Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates

(2010) Alan Kimura et al.   Clinical and Vaccine Immunology

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

(2010) Jamie Findlow et al.   CLINICAL INFECTIOUS DISEASES

Menveo®: a novel quadrivalent meningococcal CRM197conjugate vaccine against serogroups A, C, W-135 and Y

(2010) Brian Cooper et al.   Expert Review of Vaccines

Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies

(2010) Kate L. Seib et al.   INFECTION AND IMMUNITY

Complement control protein factor H: The good, the bad, and the inadequate

(2010) Viviana P. Ferreira et al.   MOLECULAR IMMUNOLOGY

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

(2010) Davide Serruto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

(2010) J. Donnelly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection

(2010) Kate L. Seib et al.   VACCINE

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage

(2010) Dlawer A.A. Ala’Aldeen et al.   VACCINE

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus

(2010) Marzia M. Giuliani et al.   VACCINE

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

(2010) Han-Qing Jiang et al.   VACCINE

Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1

(2010) Brunella Brunelli et al.   VACCINE

The Meningococcal Vaccine Candidate Neisserial Surface Protein A (NspA) Binds to Factor H and Enhances Meningococcal Resistance to Complement

(2010) Lisa A. Lewis et al.   PLoS Pathogens

NMR dynamics and antibody recognition of the meningococcal lipidated outer membrane protein LP2086 in micellar solution

(2009) Alessandro Mascioni et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Functional Comparison of the Binding of Factor H Short Consensus Repeat 6 (SCR 6) to Factor H Binding Protein from Neisseria meningitidis and the Binding of Factor H SCR 18 to 20 to Neisseria gonorrhoeae Porin

(2009) J. Shaughnessy et al.   INFECTION AND IMMUNITY

Expression of Factor H Binding Protein of Meningococcus Responds to Oxygen Limitation through a Dedicated FNR-Regulated Promoter

(2009) F. Oriente et al.   JOURNAL OF BACTERIOLOGY

Solution Structure of the Factor H-binding Protein, a Survival Factor and Protective Antigen ofNeisseria meningitidis

(2009) Francesca Cantini et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

(2009) Ellen Murphy et al.   JOURNAL OF INFECTIOUS DISEASES

The modular architecture of meningococcal factor H-binding protein

(2009) P. T. Beernink et al.   MICROBIOLOGY-SGM

Variation of the factor H-binding protein of Neisseria meningitidis

(2009) C. Brehony et al.   MICROBIOLOGY-SGM

A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups

(2009) Peter T. Beernink et al.   MOLECULAR IMMUNOLOGY

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

(2009) Muriel C. Schneider et al.   NATURE

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

(2009) Stefania Bambini et al.   VACCINE

Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis

(2009) Susanne Jacobsson et al.   VACCINE

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

(2009) Rolando Pajon et al.   VACCINE

A Novel Phase Variation Mechanism in the Meningococcus Driven by a Ligand-Responsive Repressor and Differential Spacing of Distal Promoter Elements

(2009) Matteo M. E. Metruccio et al.   PLoS Pathogens

Fine Antigenic Specificity and Cooperative Bactericidal Activity of Monoclonal Antibodies Directed at the Meningococcal Vaccine Candidate Factor H-Binding Protein

(2008) P. T. Beernink et al.   INFECTION AND IMMUNITY

Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera

(2008) D. M. Granoff et al.   INFECTION AND IMMUNITY

Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37

(2008) K. L. Seib et al.   INFECTION AND IMMUNITY

Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086

(2008) Alessandro Mascioni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Complement‐Dependent Synergistic Bactericidal Activity of Antibodies against Factor H–Binding Protein, a Sparsely Distributed Meningococcal Vaccine Antigen

(2008) Jo Anne Welsch et al.   JOURNAL OF INFECTIOUS DISEASES

Epitope Mapping of a Bactericidal Monoclonal Antibody against the Factor H Binding Protein of Neisseria meningitidis

(2008) Maria Scarselli et al.   JOURNAL OF MOLECULAR BIOLOGY

Factor H-binding protein, a unique meningococcal vaccine antigen

(2008) Mariagrazia Pizza et al.   VACCINE

Microbial complement inhibitors as vaccines

(2008) Seppo Meri et al.   VACCINE